Homocysteine potentiates amyloid β ‐induced death receptor 4‐ and 5‐mediated cerebral endothelial cell apoptosis, blood brain barrier dysfunction and angiogenic impairment
Ashley Carey,Rebecca Parodi‐Rullan,Rafael Vazquez‐Torres,Elisa Canepa,Silvia Fossati
DOI: https://doi.org/10.1111/acel.14106
IF: 11.005
2024-02-16
Aging Cell
Abstract:Pictorial representation of the study's results that Hhcy potentiates cerebral endothelial Aβ‐induced DR‐mediated apoptosis, barrier dysfunction, and angiogenesis impairment. High Hcy levels within the cerebral capillary lumen and brain parenchyma and Aβ accumulation in the brain parenchyma and vessel walls potentiate the activation of the DR4/5‐mediated apoptotic pathway, leading to cerebral EC death. Additionally, the combined presence of Hcy and Aβ exacerbate the loss of cerebral EC barrier integrity, leading to BBB permeability. Cerebral EC death and BBB permeability would require activation of angiogenesis to restore homeostasis to the cerebral environment and maintain proper cerebral perfusion, but combined presence of Hcy and Aβ also exacerbate angiogenic deficits. Thus, Hhcy exacerbates Aβ‐mediated cerebral EC dysfunction and potentiates the loss of proper vascular repair mechanisms, leading to a vicious cycle that increases AD pathology. Cerebrovascular dysfunction has been implicated as a major contributor to Alzheimer's Disease (AD) pathology, with cerebral endothelial cell (cEC) stress promoting ischemia, cerebral‐blood flow impairments and blood–brain barrier (BBB) permeability. Recent evidence suggests that cardiovascular (CV)/cerebrovascular risk factors, including hyperhomocysteinemia (Hhcy), exacerbate AD pathology and risk. Yet, the underlying molecular mechanisms for this interaction remain unclear. Our lab has demonstrated that amyloid beta 40 (Aβ40) species, and particularly Aβ40‐E22Q (AβQ22; vasculotropic Dutch mutant), promote death receptor 4 and 5 (DR4/DR5)‐mediated apoptosis in human cECs, barrier permeability, and angiogenic impairment. Previous studies show that Hhcy also induces EC dysfunction, but it remains unknown whether Aβ and homocysteine function through common molecular mechanisms. We tested the hypotheses that Hhcy exacerbates Aβ‐induced cEC DR4/5‐mediated apoptosis, barrier dysfunction, and angiogenesis defects. This study was the first to demonstrate that Hhcy specifically potentiates AβQ22‐mediated activation of the DR4/5‐mediated extrinsic apoptotic pathway in cECs, including DR4/5 expression, caspase 8/9/3 activation, cytochrome‐c release and DNA fragmentation. Additionally, we revealed that Hhcy intensifies the deregulation of the same cEC junction proteins mediated by Aβ, precipitating BBB permeability. Furthermore, Hhcy and AβQ22, impairing VEGF‐A/VEGFR2 signaling and VEGFR2 endosomal trafficking, additively decrease cEC angiogenic capabilities. Overall, these results show that the presence of the CV risk factor Hhcy exacerbates Aβ‐induced cEC apoptosis, barrier dysfunction, and angiogenic impairment. This study reveals specific mechanisms through which amyloidosis and Hhcy jointly operate to produce brain EC dysfunction and death, highlighting new potential molecular targets against vascular pathology in comorbid AD/CAA and Hhcy conditions.
cell biology,geriatrics & gerontology